1-phenyl-2-o-tolylethanamine | 42291-05-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-phenyl-2-o-tolylethanamine
• 英文别名: 1-phenyl-2-(o-tolyl)ethan-1-amine；2-(2-Methylphenyl)-1-phenylethan-1-amine；2-(2-methylphenyl)-1-phenylethanamine
• CAS: 42291-05-4
• 化学式: C₁₅H₁₇N
• mdl: MFCD09807569
• 分子量: 211.307
• InChiKey: JQQWNEQYFLLVBY-UHFFFAOYSA-N

物化性质

• 沸点：
  319.9±11.0 °C(Predicted)
• 密度：
  1.037±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  phenyl (2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)carbamate 、 1-phenyl-2-o-tolylethanamine 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 1-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(1-phenyl-2-o-tolylethyl)urea
  参考文献：
  名称：

  [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  [FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA

  摘要：

  公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。

  公开号：

  WO2014078331A1
• 作为产物：
  描述：

  邻二甲苯 、 苯甲醛 在 caesium carbonate 、 lithium hexamethyldisilazane 作用下， 反应 12.0h， 以78%的产率得到1-phenyl-2-o-tolylethanamine
  参考文献：
  名称：

  碱性金属催化甲苯对苯的一锅氨基苄基化

  摘要：

  已成功开发了一种新颖且易于使用的MN（SiMe 3）2（M = Li或Na）/ Cs 2 CO 3催化原位生成的N-（三甲基甲硅烷基）亚胺与甲苯衍生物的苄基化反应。该催化剂对苄基位置的甲苯去质子表现出高化学选择性。一锅合成具有优异效率和宽泛的官能团耐受性的各种生物活性1,2-二芳基乙胺的例子说明了该系统的实用性。

  DOI：

  10.1021/acs.orglett.9b02737

文献信息

• Compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：Konradi W. Andrei

  公开号：US20050261293A1

  公开（公告）日：2005-11-24

  Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及一种能够结合VLA-4的化合物。其中某些化合物还能够抑制白细胞黏附，特别是通过VLA-4介导的白细胞黏附。这样的化合物可用于治疗哺乳动物患者（例如人类）的炎症性疾病，例如哮喘、阿尔茨海默病、动脉硬化、艾滋病痴呆、糖尿病、炎性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可用于治疗多发性硬化等炎症性脑部疾病。
• Process for producing benzoxazine derivative and production intermediate thereof
  申请人：Sato Kouji

  公开号：US20060014947A1

  公开（公告）日：2006-01-19

  Processes for producing antibacterial agents and intermediates useful in producing antibacterial agents are provided and include producing compound (VI-a) in accordance with the following reaction schema, as well as production intermediates thereof.

  提供了用于生产抗菌剂和用于生产抗菌剂的中间体的过程，包括按照以下反应方案生产化合物（VI-a），以及其生产中间体。
• N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160272592A1

  公开（公告）日：2016-09-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  式I的化合物或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n的定义如本文所述，是TrkA激酶的抑制剂，可用于治疗可通过TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、Sjogren综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
• Method of obtaining optically active half esters
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0092194A1

  公开（公告）日：1983-10-26

  A method of separating optically active half esters comprising optically resolving a mixture of a (4S,5R)-1,3-dibenzyl-5-alkoxy or alkenyloxycarbonyl-2-oxoimidazolidine-4-carboxylic acid and a (4R,5S)-1,3-dibenzyl-5-alkoxy or alkenyloxycarbonyl-2-oxoimidazolidine-4-carboxylic acid, each being represented by the formula (I): wherein R1 is an alkyl group or an alkenyl group, each having 1 to 5 carbon atoms; Bzl is a benzyl group; * indicates an asymmetric carbon atom; and the 4- and 5-positions are a cis-configuration, using an optically active d- or 1-amine represented by the formula (II): wherein R2 and R3 are each a hydrogen atom, a halogen atom or methyl group; and indicates an asymmetric carbon atom; and the eforementioned half esters are disclosed. A method for the preparation of an optically active (4S,5R)-cis-1,3-dibenzyl-5-methoxy- or ethoxycarbonyl-2-oxoimidazolidine-4-carboxylic acid (la') or (4R,5S)-cis-1,3-dibenzyl-5-methoxy- or ethoxycarbonyl-2-oxoimidazolidine-4-carboxylic acid (Ib'), comprising preferentially crystallizing (Ia') or (Ib') from a supersaturated solution where (la' ) and (Ib') are copresent in the presence of crystals of the same type of optically active half ester as that to be crystallized, is also disclosed.

  一种分离光学活性半酯的方法，包括光学解析(4S,5R)-1,3-二苄基-5-烷氧基或烯酰氧基羰基-2-氧代咪唑烷-4-羧酸和(4R,5S)-1,3-二苄基-5-烷氧基或烯酰氧基羰基-2-氧代咪唑烷-4-羧酸的混合物，各自由式(I)表示： 其中 R1 是烷基或烯基，各具有 1 至 5 个碳原子；Bzl 是苄基；* 表示不对称碳原子；4 位和 5 位为顺式构型，使用由式（II）表示的具有光学活性的 d- 或 1-胺： 其中 R2 和 R3 各为氢原子、卤素原子或甲基；且表示不对称碳原子；本发明公开了上述半酯。一种制备光学活性(4S,5R)-顺式-1,3-二苄基-5-甲氧基-或乙氧基羰基-2-氧代咪唑烷-4-羧酸(la')或(4R,5S)-顺式-1,3-二苄基-5-甲氧基-或乙氧基羰基-2-氧代咪唑烷-4-羧酸(Ib')的方法、本发明还公开了(Ia')或(Ib')从过饱和溶液中优先结晶的方法，其中(la')和(Ib')在与待结晶的光学活性半酯类型相同的晶体存在下共存。
• A method for optical resolution of phenylacetic acid derivative
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0208948A2

  公开（公告）日：1987-01-21

  Alpha-isopropyl-p-chlorophenylacetic acid, which is an acid moiety of the pyrethroidal ester pesticides is subjected to optical resolution using optically active alpha-phenyl-beta-p-tolylethylamine or optically active alpha-phenylethylamine, as the optical resolution agent. The reaction of the acid with the amine is carried out in a hydrophobic organic solvent, such as aliphatic and aromatic hydrocarbons, in the presence of water, until the desired salt of the acid with the amine is separated therein through selective crystallization.

  使用光学活性α-苯基-β-对甲苯乙胺或光学活性α-苯基乙胺作为光学分解剂，对拟除虫菊酯农药的酸（α-异丙基-对氯苯乙酸）进行光学分解。酸与胺的反应是在疏水性有机溶剂（如脂肪族和芳香族烃）中，在有水的情况下进行的，直到通过选择性结晶分离出所需的酸与胺的盐为止。